Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.40 |
| ▸ | HTR3A | P46098 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 9/20 | 0.34 |
| ▸ | HTR2A | P28223 | 4/20 | 0.34 |
| ▸ | HTR2B | P41595 | 4/20 | 0.34 |
| ▸ | HTR6 | P50406 | 4/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3860706 | 1.00 | HTR1A (0.40) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3856531 | 1.00 | HTR1A (0.40) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3856535 | 1.00 | HTR1A (0.40) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3860709 | 1.00 | HTR1A (0.40) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13688254 | 0.88 | HTR2A (0.32) | HTR2CHTR2AHTR2BDHFR | |
| SCHEMBL13688250 | 0.87 | HTR1A (0.42) | HTR1AHTR3AHTR2CHTR6DHFR | |
| SCHEMBL3858133 | 0.87 | HTR1A (0.42) | HTR1AHTR3AHTR2CHTR6DHFR | |
| SCHEMBL13688249 | 0.84 | HTR2C (0.40) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14612797 | 0.84 | HTR2C (0.34) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3863376 | 0.84 | HTR2C (0.40) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592454-B2 | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-22 | — | — | US | disclosed |
| US-20050239768-A1 | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239768-A1 | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists | HTR1A, HTR7, HTR1D | HTR1A 1/4885HTR3A 4/4885CYP1A2 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.